腹膜后肉瘤（RPS）：一项系统综述。

IF 5 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-06-04 DOI:10.1007/s11912-025-01690-2

Ilaria Caturegli, Elizabeth J Lilley, Mark Fairweather, Jiping Wang, Chandrajit P Raut

{"title":"腹膜后肉瘤（RPS）：一项系统综述。","authors":"Ilaria Caturegli, Elizabeth J Lilley, Mark Fairweather, Jiping Wang, Chandrajit P Raut","doi":"10.1007/s11912-025-01690-2","DOIUrl":null,"url":null,"abstract":"Retroperitoneal sarcomas (RPS) are a group of rare malignancies with many histologic types. Surgery is the hallmark of curative therapy for non-metastatic disease with the extent of resection depending on the histology. RECENT FINDINGS: Neoadjuvant therapies have limited response and efficacy in RPS; however, the benefit, regimen, and timing depend on histology. Innovative therapeutics are emerging and may prove promising. PURPOSE OF REVIEW: This review discusses the work-up, management, and advances in the field of retroperitoneal sarcoma.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retroperitoneal Sarcoma (RPS): A Systematic Review.\",\"authors\":\"Ilaria Caturegli, Elizabeth J Lilley, Mark Fairweather, Jiping Wang, Chandrajit P Raut\",\"doi\":\"10.1007/s11912-025-01690-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Retroperitoneal sarcomas (RPS) are a group of rare malignancies with many histologic types. Surgery is the hallmark of curative therapy for non-metastatic disease with the extent of resection depending on the histology. RECENT FINDINGS: Neoadjuvant therapies have limited response and efficacy in RPS; however, the benefit, regimen, and timing depend on histology. Innovative therapeutics are emerging and may prove promising. PURPOSE OF REVIEW: This review discusses the work-up, management, and advances in the field of retroperitoneal sarcoma.\",\"PeriodicalId\":10861,\"journal\":{\"name\":\"Current Oncology Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Oncology Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11912-025-01690-2\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01690-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

腹膜后肉瘤（RPS）是一组罕见的恶性肿瘤，具有多种组织学类型。手术是治疗非转移性疾病的标志，切除的程度取决于组织学。最新发现：新辅助治疗对RPS的反应和疗效有限；然而，益处、方案和时间取决于组织学。创新的治疗方法正在出现，并可能被证明是有前途的。综述目的：本文综述了腹膜后肉瘤的检查、治疗和进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Retroperitoneal Sarcoma (RPS): A Systematic Review.

Retroperitoneal sarcomas (RPS) are a group of rare malignancies with many histologic types. Surgery is the hallmark of curative therapy for non-metastatic disease with the extent of resection depending on the histology. RECENT FINDINGS: Neoadjuvant therapies have limited response and efficacy in RPS; however, the benefit, regimen, and timing depend on histology. Innovative therapeutics are emerging and may prove promising. PURPOSE OF REVIEW: This review discusses the work-up, management, and advances in the field of retroperitoneal sarcoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.